Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society
December 03, 2021 10:01 ET
|
Neurona Therapeutics
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase...
Neurona Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021 16:01 ET
|
Neurona Therapeutics
SAN FRANCISCO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders,...
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021
November 08, 2021 08:00 ET
|
Neurona Therapeutics
IND cleared by the FDA to enable initiation of Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant focal epilepsy Supporting preclinical data demonstrate seizure-freedom in up to 68%...
Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients
November 04, 2021 08:00 ET
|
Neurona Therapeutics
SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders,...
Neurona Therapeutics Appoints Brad Margus to its Board of Directors
October 20, 2021 16:02 ET
|
Neurona Therapeutics
SAN FRANCISCO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders,...
Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders
June 22, 2021 08:30 ET
|
Neurona Therapeutics
Syndicate includes premier healthcare investors steeped in neurology Erica Whittaker, Ph.D., head of UCB Ventures, joins Neurona’s board of directors Latest financing brings total...
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)
June 16, 2021 08:00 ET
|
Neurona Therapeutics
Supporting data in preclinical model of drug-resistant epilepsy demonstrate seizure-freedom in 70% of the NRTX-1001 cell therapy treatment group versus 5% in the control group Data demonstrate...
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy
April 19, 2021 08:00 ET
|
Neurona Therapeutics
SAN FRANCISCO, April 19, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing neural cell therapies for the treatment of neurological disorders, today announced the...